Tumor necrosis factor-alpha and interleukin 4 in myeloma cell precursor differentiation.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Leukemia and Lymphoma

• Publication date

  1996-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3109/10428199609067576PMID 8907266
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interleukin-6 in human multiple myeloma.

  1995cited by this paper
• The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma.

  1994cited by this paper
• Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma.

  1994cited by this paper
• Tumour necrosis factor-alpha and interleukin 4 promote the differentiation of myeloma cell precursors in multiple myeloma.

  1994cited by this paper
• Tumour necrosis factor‐α and interleukin 4 promote the differentiation of myeloma cell precursors in multiple myeloma

  1994cited by this paper
• Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma.

  1994cited by this paper
• Immunoglobulin V regions and the B cell.

  1994cited by this paper
• The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell

  1993cited by this paper
• Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas

  1993cited by this paper
• Failure of IL-3 plus IL-6 to induce the proliferation and differentiation of malignant plasma cell precursors from peripheral blood in multiple myeloma.

  1993cited by this paper
• Effects of interleukin-3 and interleukin-6 on peripheral blood cells from multiple myeloma patients and their clinical significance.

  1992cited by this paper
• Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients.

  1992cited by this paper
• In vitro growth of human multiple myeloma: implications for biology and therapy.

  1992cited by this paper
• Perspectives on the origins of multiple myeloma and plasmacytomas in mice.

  1992cited by this paper
• Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation.

  1992cited by this paper
• Circulating peripheral blood plasma cells in multiple myeloma.

  1992cited by this paper
• Myeloma phenotype: clues to disease origin and manifestation.

  1992cited by this paper
• In vitro Ig‐synthesis and proliferative activity in multiple myeloma are stimulated by different growth factors

  1991cited by this paper
• T cell depletion using anti-CD2 coated magnetic beads simplifies the detection of peripheral blood plasma cells.

  1991cited by this paper
• Detection of minimal residual myeloma cells by dual parameter analysis of DNA and cytoplasmic immunoglobulin.

  1991cited by this paper
• Cytokine production in patients with monoclonal gammapathies.

  1991cited by this paper
• Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells.

  1991cited by this paper
• Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression.

  1991cited by this paper
• The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma.

  1990cited by this paper
• Markers of multiple hematopoietic-cell lineages in multiple myeloma.

  1990cited by this paper
• Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms.

  1990cited by this paper
• Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells.

  1990cited by this paper
• Autocrine growth by two cytokines, interleukin-6 and tumor necrosis factor alpha, in the myeloma cell line KHM-1A.

  1990cited by this paper
• Immunophenotypic analysis of lymphocytes and myeloma cells in patients with multiple myeloma.

  1990cited by this paper
• The role of interleukin‐1 and tumour necrosis factor‐α in human multiple myeloma

  1990cited by this paper
• Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells [see comments]

  1990cited by this paper
• Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.

  1989cited by this paper
• Circulating monoclonal B lymphocytes in multiple myeloma

  1989cited by this paper
• BSF‐2/IL‐6 does not augment lg secretion but stimulates proliferation in myeloma cells

  1989cited by this paper
• Detection of monoclonal B lymphocytes in bone marrow and peripheral blood of multiple myeloma patients by immunoglobulin gene rearrangement studies

  1989cited by this paper
• Production of cytokines by bone marrow cells obtained from patients with multiple myeloma.

  1989cited by this paper
• Production of cytokines by bone marrow cells obtained from patients with multiple myeloma

  1989cited by this paper
• Plasma cell myeloma--new biological insights and advances in therapy.

  1989cited by this paper
• Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma

  1989cited by this paper
• Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement.

  1988cited by this paper
• Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies.

  1988cited by this paper
• Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

  1988cited by this paper
• Delineation of a novel pre-B cell component in plasma cell myeloma: immunochemical, immunophenotypic, genotypic, cytologic, cell culture, and kinetic features.

  1987cited by this paper
• Evidence for peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma.

  1987cited by this paper
• Delineation of a novel pre-B cell component in plasma cell myeloma: immunochemical, immunophenotypic, genotypic, cytologic, cell culture, and kinetic features

  1987cited by this paper
• Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.

  1985cited by this paper
• Cytoplasmic immunoglobulin content in multiple myeloma.

  1985cited by this paper
• Monoclonal B Lymphocytes in Multiple Myeloma

  1980cited by this paper
• Studies on the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation

  1979cited by this paper
• A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

  1975cited by this paper

• A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma

  2021cites this paper
• Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma

  2019cites this paper
• Association between tumor necrosis factor alpha gene polymorphisms and multiple myeloma risk: an updated meta-analysis

  2018cites this paper
• Interactions between SNPs affecting inflammatory response genes are associated with multiple myeloma disease risk and survival

  2017cites this paper
• Interleukin-6 and interleukin-4 levels in multiple myeloma and correlation of interleukin-6 with β2 microglobulin and serum creatinine

  2015cites this paper
• IL-21 and other serum proinflammatory cytokine levels in patients with multiple myeloma at diagnosis.

  2014cites this paper
• The Immune Microenvironment of Myeloma

  2011cites this paper
• Dysregulation in T helper 1/T helper 2 cytokine ratios in patients with multiple myeloma

  2010cites this paper
• Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone.

  2010cites this paper
• Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells

  2008cites this paper
• Transendothelial Migration of Myeloma Cells Is Increased by Tumor Necrosis Factor (TNF)-α via TNF Receptor 2 and Autocrine Up-Regulation of MCP-1

  2004cites this paper
• A review of the cytokine network in multiple myeloma

  2003cites this paper
• Determination of Plasma Cell Secreting Potential as an Index of Maturity of Myelomatous Cells and a Strong Prognostic Factor

  2002cites this paper
• Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma.

  2002cites this paper
• Novel cytokines in growth control and bone disease of multiple myeloma

  2001cites this paper
• Interleukin-6 and the network of several cytokines in multiple myeloma: an overview of clinical and experimental data.

  2001cites this paper
• High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment.

  2000cites this paper
• Impaired Preneoplastic Changes and Liver Tumor Formation in Tumor Necrosis Factor Receptor Type 1 Knockout Mice

  2000cites this paper
• Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma.

  1999cites this paper
• Expression of interleukin‐1β and tumour necrosis factor‐α in plasma cells from patients with multiple myeloma

  1999cites this paper
• Interleukin‐15 blocks apoptosis and induces proliferation of the human myeloma cell line OH‐2 and freshly isolated myeloma cells

  1999cites this paper
• Apoptosis-induced by TRAIL AND TNF-alpha in human multiple myeloma cells is not blocked by BCL-2.

  1999cites this paper